Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Genitourinary 1

Conditions

Sexuality 1Sexual Dysfunction, Physiological 1Radiation Injuries 1Prostatic Neoplasms 1Erectile Dysfunction 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × ArginMax × Clear all
NCT00459134 2021-09-28

L-Arginine Supplements in Treating Women Who Are Cancer Survivors

Wake Forest University Health Sciences

Phase NA Completed
186 enrolled 11 charts
Other

Sexual Dysfunction, Physiological, Sexuality

NCT01105130 2021-09-28

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

Wake Forest University Health Sciences

Phase 2 Completed
140 enrolled 13 charts
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡